Why are GLP-1 medicines important before surgery and endoscopy?

GLP-1 medicines (semaglutide, tirzepatide) can slow stomach emptying. Tell the team early before surgery or endoscopy, and do not stop the medicine yourself.

What do these medicines change in the stomach?

This article explains why GLP-1 medicines used for weight loss and diabetes need attention before surgery and endoscopy. 11 These medicines slow down stomach emptying; during a general anaesthetic or deep sedation (being put to sleep with medicine), this increases the risk of stomach contents entering the lungs. 11 Food may remain in the stomach on the day of the procedure even if the usual fasting instructions are followed. 1

Stomach contents entering the lungs is called aspiration; it is rare, but is a high-risk complication that can be fatal. 5 For this reason, the instructions before the procedure and the anaesthetic method may need to be changed. 11

In 2024, the European Medicines Agency requested that the following warning be added to product information: the risk of contents remaining in the stomach should be considered before a general anaesthetic or deep sedation. 7 The warning covers semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide and lixisenatide. 7

What do the guidelines recommend?

In 2023, the American Society of Anesthesiologists (ASA) recommended considering stopping weekly medicine one week before the procedure and daily medicine on the day of the procedure. 6 The multi-society guidance supported by the ASA in 2024, however, calls for the decision to be made jointly with you, the procedure and anaesthesia team and the doctor who prescribed the medicine, weighing up your individual risk. 1 The medicine may be continued before surgery in people who are not at high risk of delayed stomach emptying and aspiration. 1 The guidance considers risk higher in the following situations: during dose escalation, at a high dose, with weekly use, with gastrointestinal symptoms and with other conditions that delay stomach emptying. 1

The Australian and New Zealand guidance (2025) also does not recommend stopping the medicine before a planned procedure. 4 The same guidance recommends a clear liquid diet on the day before the procedure for everyone taking these medicines. 4 The guidelines do not agree on everything; their recommendations on managing medicines and fasting differ considerably. 3

What should you do?

Tell your team days in advance that you take the medicine: preparations such as dietary changes may take time. 1 Tell them even if you obtained it without a prescription or do not consider it a medicine. 4 Do not stop your GLP-1 medicine, skip doses or change your dose on your own; first consult the doctor who prescribed it or the team carrying out the procedure. 11 Stopping long-acting medicines (dulaglutide, semaglutide, tirzepatide) for 1–2 weeks is unlikely to change the slowing of stomach emptying; tell the team even if you have stopped. 4

Tell the team if you have severe nausea, vomiting or cannot keep food and drink down; it is recommended that you be referred to the doctor who prescribed the medicine before a planned procedure. 3 If you continue to vomit and cannot keep fluids down, do not wait until the day of the procedure; consult a doctor immediately. If you cannot reach a doctor, have an assessment at a healthcare facility without delay. 15

If you are given a clear liquid diet, do not eat solid food throughout the day before the procedure. 10 A clear liquid has no particles in it and can usually be seen through: examples include water, tea or coffee without milk, and clear apple juice. 10 Drinks containing milk and fruit juices with pulp do not belong in this group; Turkish coffee with grounds is also unsuitable because it contains particles. 10 Follow your own team's instructions about the liquid diet, water and fasting times; written information of this kind does not replace the information given by your anaesthetist. 10 If you could not follow the instructions, tell the hospital as soon as possible and say when you started fasting; your procedure may still be able to go ahead. 10

Diabetes and SGLT2 medicines

If you have diabetes (especially if you use insulin) or are preparing your bowel for a colonoscopy, ask your doctor for instructions. 10 Do not stop or rapidly reduce your insulin without consulting your doctor: ketoacidosis (a build-up of acid in the blood) has been reported when insulin used alongside a GLP-1 medicine is rapidly reduced or stopped. 11 Semaglutide can lower blood sugar, especially when used with other diabetes medicines; ask your doctor in advance what to do while fasting. 8

SGLT2 inhibitors are a separate group from GLP-1 medicines; the recommendations below on stopping and restarting apply only to this group. 2 Dapagliflozin, empagliflozin and canagliflozin belong to this group. 12 The consensus statement from England recommends not taking these medicines on the day before and the day of a planned operation; this may be less applicable to endoscopy and emergency surgery. 2 Recommendations differ on when to stop; ask your doctor and procedure team about the timing. 2 For people with diabetes starting a very low-calorie diet before surgery, the SGLT2 medicine should be stopped at the start of the diet and diabetes treatment adjusted if necessary; make this plan with your doctor before the diet. 2 The main concern with these medicines is ketoacidosis, which can develop even when blood sugar is normal; for people discharged on the same day, restarting the medicine is recommended once they begin eating and drinking normally (usually after 24–48 hours). 2

Ketoacidosis is a serious condition that can occur in people with diabetes as well as in those taking SGLT2 medicines; surgery is also among its causes. 13 Symptoms include thirst, frequent urination, nausea or vomiting, abdominal pain, breathing more deeply than normal, fruity-smelling breath, drowsiness and confusion. 13 If you have these symptoms and do not know your ketone level or have not been diagnosed with diabetes, call 112 or go to the nearest emergency department. 13 Do not drive yourself to the emergency department; ask someone to take you or call an ambulance. 13

If you take an SGLT2 medicine, a urine ketone test may be less reliable than a blood test. 14 If you take an SGLT2 medicine and develop nausea or vomiting, abdominal pain, fast and deep breathing, drowsiness, sweet-smelling breath or a sweet or metallic taste in your mouth, seek medical help immediately, even if your blood sugar is not very high or your urine test is normal. 12, 14

What is still uncertain

The evidence is limited: the Australian and New Zealand guidance states that its recommendations are based on case reports and retrospective data, and that the balance of benefits and risks of continuing the medicine remains uncertain. 4 Having no gastrointestinal symptoms also does not reliably show that your stomach is empty. 4

A study conducted in the United Kingdom and published in 2026 followed 47,039 adults who underwent procedures under the supervision of an anaesthetist. 9 Aspiration or stomach contents coming up into the mouth occurred in 1.41% of those taking the medicine (1 in 71 people) and 0.12% of those not taking it. 9 Your individual risk should be assessed separately according to the medicine, you and the procedure. 2

This article is for general information and does not replace an examination.

Sources

  1. Kindel TL, Wang AY, Wadhwa A, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgical Endoscopy. 2025;39(1):180-183 (online 29 October 2024; the same text was also published in Surgery for Obesity and Related Diseases and Clinical Gastroenterology and Hepatology).
  2. El-Boghdadly K, Dhesi J, Fabb P, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement. Anaesthesia. 2025;80(4):412-424.
  3. Oprea AD, Ostapenko LJ, Sweitzer B, et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. British Journal of Anaesthesia. 2025;135(1):48-78.
  4. Hocking SL, Scott DA, Remedios ML, et al. 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists. Anaesthesia and Intensive Care. 2025;53(5):300-306.
  5. Australian and New Zealand College of Anaesthetists (ANZCA). GLP-1 receptor agonists - clinical practice recommendations (page and frequently asked questions). Accessed: 5 October 2026.
  6. Joshi GP, Abdelmalak BB, Weigel WA, et al. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. American Society of Anesthesiologists, 29 June 2023 (the page includes an October 2024 update note).
  7. European Medicines Agency, PRAC. PRAC recommendations on signals adopted at the 8-11 July 2024 PRAC meeting (EMA/PRAC/312286/2024), section 1.4. EMA, 2024.
  8. NHS (England). Semaglutide: a medicine to manage type 2 diabetes or treat obesity. Last reviewed: 15 May 2026.
  9. Potter TE, Cronin JN, Kua J, et al. (GLIMPSE). Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study. Anaesthesia. 2026 (online 16 September 2026; abstract only).
  10. Australian and New Zealand College of Anaesthetists (ANZCA). Preparing for your medical procedure when taking some diabetes and/or weight loss medications (patient information sheet, V5, June 2025). Accessed: 5 October 2026.
  11. Medicines and Healthcare products Regulatory Agency (MHRA). GLP-1 medicines for weight loss and diabetes: what you need to know (patient guide). GOV.UK, first published 5 June 2025, updated 5 February 2026. Accessed: 5 October 2026.
  12. Medicines and Healthcare products Regulatory Agency (MHRA). SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. Drug Safety Update, volume 9, issue 9, 18 April 2016. Accessed: 5 October 2026.
  13. NHS (England). Diabetic ketoacidosis. Last reviewed: 8 June 2023 (the next review was due on 8 June 2026 and is overdue). Accessed: 5 October 2026.
  14. Medicines and Healthcare products Regulatory Agency (MHRA). SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. Drug Safety Update, 18 March 2020. Accessed: 6 October 2026.
  15. NHS (England). Diarrhoea and vomiting. Last reviewed: 21 December 2023 (next review: 21 December 2026). The page is written for services in England. Accessed: 6 October 2026.

I would like a call back to arrange an appointment · Contact